Sivik Global Healthcare LLC Purchases Shares of 45,000 Revvity Inc. $RVTY

Key Points

• Sivik Global Healthcare LLC has acquired 45,000 shares of Revvity Inc., valued at approximately $4.35 million, making it the company's 24th largest holding.
• Several analysts have recently downgraded Revvity's stock price targets, with Barclays lowering it from $110 to $100 and Stifel Nicolaus from $120 to $110, while maintaining a "hold" rating.
• Revvity recently announced a quarterly dividend of $0.07 per share, equating to an annual yield of 0.3%, with a payout ratio of 11.86%.

Sivik Global Healthcare LLC acquired a new position in shares of Revvity Inc. (NYSE:RVTY - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 45,000 shares of the company's stock, valued at approximately $4,352,000. Revvity accounts for about 1.2% of Sivik Global Healthcare LLC's holdings, making the stock its 24th largest holding.

A number of other large investors have also recently made changes to their positions in RVTY. Wealth Enhancement Advisory Services LLC increased its holdings in Revvity by 3.8% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 5,139 shares of the company's stock worth $544,000 after buying an additional 187 shares during the period. Ritholtz Wealth Management acquired a new stake in shares of Revvity in the first quarter worth $210,000. Amalgamated Bank raised its holdings in shares of Revvity by 1.0% during the first quarter. Amalgamated Bank now owns 23,777 shares of the company's stock worth $2,516,000 after purchasing an additional 227 shares during the last quarter. Family Legacy Financial Solutions LLC purchased a new position in shares of Revvity during the second quarter worth $5,351,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Revvity by 11.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,415 shares of the company's stock valued at $1,417,000 after purchasing an additional 1,343 shares during the last quarter. 86.65% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Barclays decreased their price objective on Revvity from $110.00 to $100.00 and set an "overweight" rating for the company in a report on Thursday, October 2nd. Wall Street Zen lowered Revvity from a "buy" rating to a "hold" rating in a research report on Sunday, August 3rd. Stifel Nicolaus cut their target price on shares of Revvity from $120.00 to $110.00 and set a "hold" rating for the company in a report on Tuesday, July 29th. Evercore ISI decreased their target price on shares of Revvity from $108.00 to $106.00 and set an "outperform" rating for the company in a research note on Tuesday, October 7th. Finally, Weiss Ratings lowered shares of Revvity from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Wednesday. Ten analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Revvity has a consensus rating of "Moderate Buy" and a consensus target price of $117.93.

Revvity Price Performance

Revvity stock opened at $88.36 on Friday. The stock has a market capitalization of $10.26 billion, a P/E ratio of 37.44, a P/E/G ratio of 2.95 and a beta of 0.98. The company's fifty day moving average price is $88.08 and its 200 day moving average price is $92.83. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.75 and a current ratio of 3.33. Revvity Inc. has a 1 year low of $81.36 and a 1 year high of $129.50.

Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The company reported $1.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.04. The business had revenue of $720.28 million for the quarter, compared to the consensus estimate of $711.26 million. Revvity had a net margin of 10.19% and a return on equity of 7.66%. The company's revenue was up 4.1% compared to the same quarter last year. During the same period last year, the firm posted $1.22 earnings per share. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. As a group, equities research analysts anticipate that Revvity Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 17th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date is Friday, October 17th. Revvity's payout ratio is 11.86%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.

Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity Inc. (NYSE:RVTY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.